OncBioMune Pharmaceuticals Competitors and Similar CompaniesClear all
OncBioMune Pharmaceuticals's competitors and similar companies include Olema Oncology, Kyowa Kirin, Calithera Biosciences and Moleculin Biotech.
 Olema Oncology Olema Oncology (also known as Olema Pharmaceuticals) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers. |  Kyowa Kirin Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. |  Calithera Biosciences Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. |  Moleculin Biotech Moleculin Biotech is a pharmaceutical company focused on the development of anti-cancer drug candidates. | ||
Founding Date | Founding Date 2005 | Founding Date 2007 | Founding Date 2008 | Founding Date 2010 | Founding Date 2006 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Baton Rouge, US HQ | Locations San Francisco, US HQ San Francisco, US | Locations South San Francisco, US HQ | Locations Houston, US HQ | |
Employees | Employees 3 | Employees 9630% increase | Employees 5,669 | Employees 798% increase | Employees 176% decrease |
Valuation ($) | Valuation ($) 8.7 b | Valuation ($) 679.2 m | Valuation ($) 8.8 b | Valuation ($) 29.2 k | Valuation ($) 7.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $124.7k (FY, 2023) | Revenue (est.) N/A | Revenue (est.) ¥496.8b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $126.2k (FY, 2023) | Cost of goods N/A | Cost of goods ¥114.3b (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $480.6k (FY, 2023) | Gross profit N/A | Gross profit ¥383.4b (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($30.9m) (FY, 2023) | Net income ($162.5m) (FY, 2025) | Net income ¥67b (FY, 2025) | Net income ($39.7m) (FY, 2022) | Net income ($33.6m) (FY, 2025) |
Operating ⚠ | |||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 1 (Q3, 2020) | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 145.1m | Total funding raised N/A | Total funding raised $ 105m | Total funding raised $ 491k |
For sources of this data, please see the company profile
View Company Profiles
Olema Oncology
HQ
San Francisco, US
Employees
96↑ 30% increase
Olema Oncology (also known as Olema Pharmaceuticals) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers.
View companyKyowa Kirin
HQ
Tokyo, JP
Employees
5,669
Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system.
View companyCalithera Biosciences
HQ
South San Francisco, US
Employees
79↑ 8% increase
Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.
View companyMoleculin Biotech
HQ
Houston, US
Employees
17↓ 6% decrease
Moleculin Biotech is a pharmaceutical company focused on the development of anti-cancer drug candidates.
View company